Found a way to reverse dwarf syndrome

French scientists have achieved initial success in reversing dwarf syndrome and believe that new therapies can soon be applied in humans within the next 3-5 years.

According to the article published in Medicin e Science Translational magazine, dwarfism (congenital stunting) can originate from more than 200 individual diseases and is capable of causing complicated complications. French researchers found that the disease could be treated by injecting protein into the patient.

The team created a "breakthrough" when injecting a protein molecule into mice suffering from dwarfism for 3 months, allowing them to grow as completely as other normal species.

British celebrity actor "dwarf" Warwick Davis.(Photo: Top News)

The Local quoted Elvire Gouze, an expert at the Nice Center for Mediterranean Molecular Research in Nice, France, saying: "The treatment is very simple, just need to inject a protein and it actually develops This is just the first stage and needs more steps before human trials, but so far there are no signs that it will be useless for dwarfs. "

In the experiment, the team injected proteins for mice with cartilage deficiency - a gene mutation that causes most cases of human dwarfism - twice a week over a 3-week period.

Dr. Gouze explained, 3 weeks for mice is equivalent to 15 years in humans, so the same treatment can be effective in children with lack of cartilage development, without daily protein injections. .

However, according to the study, this therapy will not be suitable for people who have passed puberty. Scientists are currently conducting additional experiments on mice to see if it may be delayed or have to start applying the treatment for dwarfism immediately after birth. Later, they expected to perform experiments on a larger animal, such as primates.

Patrick Petit-Jean, Vice President of the Association of French Small Bodies, is cautious in receiving breakthrough research results. The goal of the new method, he said, is not to eliminate dwarfism, which affects about 8,000 - 10,000 people, in France alone.